Addex Therapeutics’ Upcoming Q3 2025 Financial Report and Conference Call
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company based in Switzerland, announces its Third Quarter 2025 Financial Results report date. Set for December 4, 2025, this event is vital for shareholders and stakeholders invested in innovative healthcare solutions.
Details of the Financial Announcement and Conference Call
The financial results will be unveiled during a teleconference accessible to investors, analysts, and media at 16:00 CET. Participants can expect an overview of the company’s performance along with a comprehensive review of the ongoing product pipeline by Tim Dyer, CEO, and Mikhail Kalinichev, Head of Translational Science.
Joining the Teleconference
For those interested in participating, registration is essential to obtain unique access codes. This facilitates seamless entry into the conference call.
Important Registration Steps
To ensure a smooth experience, participants should register beforehand. A unique Personal Identification Number (PIN) will be provided to streamline the login process on the day of the call. In the last 10 minutes before the call, using the provided dial-in numbers is crucial for connectivity.
About Addex Therapeutics and its Innovations
Addex Therapeutics has carved a niche in developing small molecule allosteric modulators targeting neurological disorders. Their leading candidate, dipraglurant, is undergoing evaluation for its efficacy in brain injury recovery, highlighting its potential in treatment protocols for conditions such as post-stroke recovery and traumatic brain injuries.
Collaborations and Advancements
A partnership with Indivior focuses on advancing a GABAB PAM drug candidate aimed at addressing substance use disorders, which has successfully completed necessary IND enabling studies. Additionally, Addex is advancing a separate GABAB PAM program for chronic cough, which indicates its commitment to broadening its therapeutic applications.
Investment in Future Technologies
Further solidifying its innovative stance, Addex Therapeutics holds a 20% equity interest in Neurosterix LLC, a promising company advancing a range of allosteric modulator programs, including those targeting schizophrenia and mood disorders. This aligns with Addex’s broader vision of integrating cutting-edge science into practical therapeutic solutions.
Looking Ahead for Addex Therapeutics
The company continues to explore avenues to further its research and development. Their investment in Stalicla, a pioneering company focused on precision medicine for neurodevelopmental disorders, underscores Addex’s strategic intent to address complex medical challenges through tailored therapies.
Frequently Asked Questions
What is the date of Addex Therapeutics’ financial report?
The financial results will be reported on December 4, 2025.
Who will present during the conference call?
Tim Dyer, the CEO, and Mikhail Kalinichev, the Head of Translational Science, will provide insights during the call.
What is Addex Therapeutics known for?
Addex Therapeutics focuses on developing novel small molecule allosteric modulators for neurological disorders.
How can participants join the teleconference?
Participants must register in advance to obtain their calling details and PIN for the teleconference.
What is the significance of Addex Therapeutics’ partnership with Indivior?
This partnership aims to progress a drug candidate for substance use disorders, contributing significantly to Addex’s research portfolio.